NASDAQ$RAPP
Rapport Therapeutics Inc · Q1 2026 earnings
Q1 2026 earnings ·
Briefing
Rapport Therapeutics reported Q1 2026 collaboration revenue of $20.0M and a net loss of $19.9M.
Q1 2026 collaboration revenue was $20.0 million from the Tenacia license upfront amortization. Net loss narrowed to $19.9 million from $24.1 million as R&D was $32.7 million on RAP-219 and platform programs. No product sales yet.
- Collaboration revenue $20.0M (Tenacia license).
- Net loss $(19.9)M vs $(24.1)M prior year.
- R&D $32.7M on neuroscience pipeline.
- Cash supports clinical-stage programs.
Headline financials
Revenue & EPS history
Rapport Therapeutics Inc · Revenue · Quarterly
$20M
Forward guidance
Biotech discusses clinical milestones for RAP-219 and partnership economics without product revenue guidance.
Tailwinds
- Collaboration revenue improves loss profile vs prior year.
- Focused CNS pipeline with partner validation.
Headwinds
- No commercial product revenue yet.
- Clinical and regulatory risks on lead assets.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 2 quarterly earnings reports · overlaid with Q1 2026
+2.2%
Avg return
Earnings day
-4.2%
Avg return
5 days after
+4.7%
Avg return
30 days after
50%
1 / 2 earnings
Positive
+7.4%
Q1 2026
Best reaction
-3.0%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +7.4% | +0.4% | -2.7% | |
| Q4 2025 | -3.0% | -8.8% | +12.0% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro